Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: kas1 who wrote (348)	10/2/1998 11:38:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 642

(OT) Kas1, concerning AHP, their pipeline drugs don't seem to be that exciting or "blockbuster" (Enbrel for rheumatoid arthritis, Rapamune for prevention of transplant rejection etc.) Hence merger with MTC would be a great positive for them. I prefer MTC on the very slim chance that another pharma would come in to make a competing bid for MTC. I believe there are some lawsuits against AHP's obesity drugs. This could be a drag on the stock price. BTW, AHP would report earnings on 10/22. Regards. Anthony